Literature DB >> 19032922

Osteomalacia.

Michael Maricic1.   

Abstract

The finding of low bone mineral density with a T-score of -2.5 or below on dual energy x-ray absorptiometry is usually reported as indicating that the patient has "osteoporosis" according to the World Health Organization classification, and, in postmenopausal women, it is often assumed that this is due to estrogen deficiency. However, up to one third of postmenopausal women have a secondary cause of low density, including osteomalacia. Osteomalacia is defined as a mineralization defect caused by disorders that lead to decreased mineralization of bone. Clues from the history, physical examination, laboratory tests, and radiographs may indicate that the patient suffers from a form of osteomalacia rather than postmenopausal estrogen deficiency alone. Establishing a diagnosis of osteomalacia when present is critical to proper management of the patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19032922     DOI: 10.1007/s11914-008-0023-7

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  25 in total

1.  Pathophysiology of bone loss in patients receiving anticonvulsant therapy.

Authors:  Lorraine A Fitzpatrick
Journal:  Epilepsy Behav       Date:  2004-02       Impact factor: 2.937

2.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Tumor-induced osteomalacia: lessons learned.

Authors:  E Michael Lewiecki; Edward J Urig; Ralph C Williams
Journal:  Arthritis Rheum       Date:  2008-03

Review 5.  "Phosphatonins" and the regulation of phosphorus homeostasis.

Authors:  Theresa J Berndt; Susan Schiavi; Rajiv Kumar
Journal:  Am J Physiol Renal Physiol       Date:  2005-12

6.  Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.

Authors:  Michael F Holick; Ethel S Siris; Neil Binkley; Mary K Beard; Aliya Khan; Jennifer T Katzer; Richard A Petruschke; Erluo Chen; Anne E de Papp
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

Review 7.  Anti-epileptic medication and bone health.

Authors:  S J Petty; T J O'Brien; J D Wark
Journal:  Osteoporos Int       Date:  2006-11-08       Impact factor: 4.507

Review 8.  Secondary osteoporosis.

Authors:  Emily Stein; Elizabeth Shane
Journal:  Endocrinol Metab Clin North Am       Date:  2003-03       Impact factor: 4.741

Review 9.  Fractures, epilepsy, and antiepileptic drugs.

Authors:  Richard H Mattson; Barry E Gidal
Journal:  Epilepsy Behav       Date:  2004-02       Impact factor: 2.937

Review 10.  Musculoskeletal manifestations of osteomalacia and rickets.

Authors:  Antonio J Reginato; Juliet Arambulo Coquia
Journal:  Best Pract Res Clin Rheumatol       Date:  2003-12       Impact factor: 4.098

View more
  2 in total

1.  A kind of specific osteolytic destruction of the vertebral bodies.

Authors:  Baogan Peng; Jinhong Chen; Xiaodong Pang; Yan Hei
Journal:  BMJ Case Rep       Date:  2012-06-05

2.  Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg(CAG-A4GALT) mouse model of Fabry disease.

Authors:  Hiroki Maruyama; Atsumi Taguchi; Mariko Mikame; Hongmei Lu; Norihiro Tada; Muneaki Ishijima; Haruka Kaneko; Mariko Kawai; Sawako Goto; Akihiko Saito; Riuko Ohashi; Yuji Nishikawa; Satoshi Ishii
Journal:  FASEB Bioadv       Date:  2020-06-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.